Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it's really tough to gauge which innovative biotech firms will have something genuinely ground ...